Gene · 5454
POU3F2: POU class 3 homeobox 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. POU3F2: POU class 3 homeobox 2. Genes, record 5454. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5454
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P20265 | POU domain, class 3, transcription factor 2 | 443 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents51
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2026048797 A | 2026-03-05 | 34 | P20265 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 58840 | P20265 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 5496 | P20265 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 15507 | P20265 | Espacenet |
| JP 2025531671 A | 2025-09-25 | 18 | P20265 | Espacenet |
| JP 2025530805 A | 2025-09-17 | 29 | P20265 | Espacenet |
| EP 4573186 A1 | 2025-06-25 | 18 | P20265 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 5496 | P20265 | Espacenet |
| KR 1020250068664 A | 2025-05-16 | 29 | P20265 | Espacenet |
| EP 4524243 A1 | 2025-03-19 | 5 | P20265 | Espacenet |
1 to 10 of 51
See all 51 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,954
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | POU3F2 papers | Newest fiscal year |
|---|---|---|---|
| P50CA097186 | The Pacific Northwest Prostate Cancer SPORE | 15 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 14 | 2025 |
| R37CA241486 | Molecular mechanisms underlying lineage plasticity in prostate cancer | 8 | 2025 |
| P01CA163227 | Androgen Receptor Action in Castration Resistant Prostate Cancer | 6 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 6 | 2025 |
| R01CA097098 | Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer | 6 | 2025 |
| P30CA046592 | University of Michigan Rogel Cancer Center Support Grant 2023-2028 | 5 | 2025 |
| P50CA186786 | Michigan Prostate SPORE 2025-2030 | 5 | 2025 |
| P01CA163222 | Targetable epigenetic and transcriptional mechanisms in melanoma thatshape the microenvironment | 4 | 2025 |
| P30CA030199 | Cancer Center Support Grant (CCSG) | 4 | 2025 |
1 to 10 of 1,954Source NIH's project files
See all 1,954 nih grantsPapers1,850
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| BRN2 in lineage plasticity: a prostate cancer-focused perspective. | Endocrinology | 2026 | 42687120 | PubTator, text mining | PubMed |
| The Marine Cembranoid Sarcophine Suppressed the Progression and Recurrence of the Metastatic Castration-Resistant Prostate Cancer via Downregulating EZH2-β-Catenin-Centered Oncogenic Network. | Mar Drugs | 2026 | 42505963 | PubTator, text mining | PubMed |
| Transcription Factors in the Pathogenesis of Schizophrenia. | Life (Basel) | 2026 | 42195329 | PubTator, text mining | PubMed |
| KCTD10 as a selective cancer dependency from transcription-replication conflicts (TRCs). | Ageing Cancer Res Treat | 2026 | 42037670 | PubTator, text mining | PubMed |
| Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion. | Proc Natl Acad Sci U S A | 2026 | 41961819 | PubTator, text mining | PubMed |
| Transposable element-mediated evolutionary expansion of Sox2- and Brn2-binding regulatory modules for mammalian neural-cell differentiation. | Genome Biol | 2026 | 41952195 | PubTator, text mining | PubMed |
| Reprogramming of neuronal genome function and phenotype by astrocytes. | bioRxiv | 2026 | 41867870 | PubTator, text mining | PubMed |
| DAB2IP: unifying cardiovascular pathogenesis and cardiovascular brain crosstalk. | Front Cardiovasc Med | 2026 | 41798622 | PubTator, text mining | PubMed |
| Pitfalls in analysis and interpretation of single-cell RNA-seq data in cancer. | Neurooncol Adv | 2026 | 41769412 | PubTator, text mining | PubMed |
| Reprogramming of astrocytes into motoneuron-like cells by a Ascl1-Myt1l-Pou3f2-Isl1 cocktail. | Exp Cell Res | 2026 | 41763511 | PubTator, text mining | PubMed |
1 to 10 of 1,850
See all 1,850 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5454
GET https://conductscience.org/api/genes/v1/5454/patents?page=2